Mineralys Therapeutics (NASDAQ:MLYS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Mineralys Therapeutics (NASDAQ:MLYS) from a hold rating to a sell rating in a research report released on Saturday.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. HC Wainwright set a $56.00 price target on shares of Mineralys Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Jefferies Financial Group reiterated a “hold” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research note on Friday, March 13th. TD Cowen initiated coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They set a “buy” rating on the stock. Finally, Bank of America lifted their price target on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $49.14.

Mineralys Therapeutics Stock Up 0.6%

Shares of Mineralys Therapeutics stock opened at $29.54 on Friday. The company has a market cap of $2.44 billion, a price-to-earnings ratio of -14.41 and a beta of 0.49. The company’s 50 day moving average is $27.15 and its 200 day moving average is $33.14. Mineralys Therapeutics has a twelve month low of $12.59 and a twelve month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.04. Sell-side analysts expect that Mineralys Therapeutics will post -2.29 EPS for the current fiscal year.

Insider Activity

In other news, insider David Malcom Rodman sold 6,348 shares of the firm’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $27.66, for a total transaction of $175,585.68. Following the sale, the insider directly owned 69,792 shares in the company, valued at $1,930,446.72. This trade represents a 8.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of the firm’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $25.00, for a total transaction of $75,000.00. Following the sale, the director owned 6,200 shares in the company, valued at $155,000. The trade was a 32.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 162,291 shares of company stock valued at $4,336,414 over the last 90 days. Company insiders own 18.94% of the company’s stock.

Institutional Trading of Mineralys Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. KBC Group NV bought a new stake in shares of Mineralys Therapeutics during the 1st quarter valued at $33,000. Jennison Associates LLC raised its position in shares of Mineralys Therapeutics by 0.6% during the 1st quarter. Jennison Associates LLC now owns 1,266,174 shares of the company’s stock valued at $34,301,000 after purchasing an additional 7,521 shares during the period. Candriam S.C.A. raised its position in shares of Mineralys Therapeutics by 18.2% during the 1st quarter. Candriam S.C.A. now owns 801,904 shares of the company’s stock valued at $21,724,000 after purchasing an additional 123,517 shares during the period. Y Intercept Hong Kong Ltd raised its position in shares of Mineralys Therapeutics by 321.2% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 132,099 shares of the company’s stock valued at $3,579,000 after purchasing an additional 100,740 shares during the period. Finally, Pictet Asset Management Holding SA raised its position in shares of Mineralys Therapeutics by 21.3% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,034,438 shares of the company’s stock valued at $28,023,000 after purchasing an additional 181,555 shares during the period. 84.46% of the stock is currently owned by institutional investors.

Trending Headlines about Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Neutral Sentiment: HC Wainwright reiterated a Buy rating and $56 price target on Mineralys Therapeutics, but it lowered earnings estimates across several periods, including Q2 2026, Q3 2026, Q4 2026, FY2026, FY2027, FY2028, FY2029 and FY2030. The revisions suggest more conservative expectations for profitability, which can weigh on sentiment. MarketBeat stock page
• Positive Sentiment: Despite the lower estimates, HC Wainwright still sees long-term upside and maintained its constructive view on the company, signaling that analysts believe Mineralys can still deliver meaningful value over time. MarketBeat stock page
• Negative Sentiment: Wall Street Zen downgraded MLYS to Sell, adding pressure on the shares and likely contributing to the recent weakness in investor sentiment. Article title
• Neutral Sentiment: A separate article highlighted Mineralys Therapeutics’ post-Q1 earnings update and path forward for its lorundrostat NDA, but the headline did not indicate a major new catalyst by itself. Article title

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.